"It is profoundly important for Genmab’s future"
For the first time, patients have been dosed with a drug agent based on Genmab’s technology platform DuoBody, and the importance of this cannot be underestimated, says CEO Jan van de Winnkel – even if it is a Janssen drug and not Genmab’s own. A large portion of the company’s pipeline is based on this technology, and before long one of the company's own drugs will go clinical.
BY STEFAN SINGH KAILAY
Novartis, Gilead Sciences, Novo Nordisk, Janssen and for a while Eli Lilly. All of these large companies see something promising in Danish company Genmab’s DuoBody platform, which they use to develop potent anti-body based drugs.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
